The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3, 4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

Authors

• Norbert Galldiks
• Ian Law
• Whitney B. Pope
• Javier Arbizu
• Karl-Josef Langen

Keywords

• PET
• FET
• MET
• FDOPA
• Glioma
• Temozolomide
• Bevacizumab
• Immunotherapy
• Checkpoint inhibitors
• Pseudoprogression
• Pseudoresponse